Trial Profile
A double blind, randomised, placebo controlled, parallel group study of Sativex [dronabinol/cannabidiol] in the treatment of subjects with peripheral neuropathic pain, associated with allodynia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 24 Dec 2021 This trial has been completed in Germany and Czech Republic, according to European Clinical Trials Database record.
- 15 Jan 2007 Preliminary results have been reported.
- 25 May 2006 New trial record.